BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nieddu F, Moriondo M, De Vitis E, Ricci S, Indolfi G, Resti M, Vocale C, Landini MP, Sartor A, Azzari C. PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend? Vaccine 2017;35:1544-50. [DOI: 10.1016/j.vaccine.2017.01.064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Beutels P, Newall AT. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine 2018;36:2057-60. [PMID: 29548606 DOI: 10.1016/j.vaccine.2018.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lodi L, Ricci S, Nieddu F, Moriondo M, Lippi F, Canessa C, Mangone G, Cortimiglia M, Casini A, Lucenteforte E, Indolfi G, Resti M, Azzari C. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Severe Invasive Disease Caused by Serotype 3 Streptococcus Pneumoniae in Italian Children. Vaccines (Basel) 2019;7:E128. [PMID: 31554213 DOI: 10.3390/vaccines7040128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Alarcón ZK, Duarte C, Sanabria O, Moreno J. Streptococcus pneumoniae serotype 3 genotypes in invasive isolates from Colombia. Biomedica 2021;41:338-46. [PMID: 34214273 DOI: 10.7705/biomedica.5407] [Reference Citation Analysis]
4 Azzari C, Serranti D, Nieddu F, Moriondo M, Casini A, Lodi L, de Benedictis FM, De Vitis E, Cavone F, Cortimiglia M, Indolfi G, Lombardi E, Carloni I, Cutrera R, Lucenteforte E, Resti M, Ricci S. Significant impact of pneumococcal conjugate vaccination on pediatric parapneumonic effusion: Italy 2006-2018. Vaccine 2019;37:2704-11. [PMID: 30981627 DOI: 10.1016/j.vaccine.2019.04.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
5 LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, Lang ALS, Gillis HD, Martin I, Demczuk W, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy AE, McGeer A, Semret M, Trottier S, Valiquette L, Webster D, McNeil SA. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine 2019;37:5466-73. [PMID: 31345638 DOI: 10.1016/j.vaccine.2019.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
6 Luna CM, Pulido L, Niederman MS, Casey A, Burgos D, Leiva Agüero SD, Grosso A, Membriani E, Entrocassi AC, Rodríquez Fermepin M, Vay CA, Garcia S, Famiglietti A. Decreased relative risk of pneumococcal pneumonia during the last decade, a nested case-control study. Pneumonia (Nathan) 2018;10:9. [PMID: 30263884 DOI: 10.1186/s41479-018-0053-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Monali R, De Vita E, Mariottini F, Privitera G, Lopalco PL, Tavoschi L. Impact of vaccination on invasive pneumococcal disease in Italy 2007-2017: surveillance challenges and epidemiological changes. Epidemiol Infect 2020;148:e187. [PMID: 32418558 DOI: 10.1017/S0950268820001077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Bonanni P, Bonaccorsi G, Lorini C, Santomauro F, Tiscione E, Boccalini S, Bechini A. Focusing on the implementation of 21st century vaccines for adults. Vaccine 2018;36:5358-65. [PMID: 28807604 DOI: 10.1016/j.vaccine.2017.07.100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]